Ramon Alemany

9PUBLICATIONS
51CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 08, 2026
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

|Feb 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.

Xavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero

|Jan 05, 2024
Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors.

M Costa-Garcia, J J Rojas, M D Ramos

|Jul 14, 2023
SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy.

Juan José Soto-Castillo, Lucía Llavata-Marti, Roser Fort-Culillas

|Feb 02, 2021
Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.

Martí Farrera-Sal, Laura Moya-Borrego, Miriam Bazan-Peregrino

|Dec 01, 2020
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.

Juri Kiyokawa, Yoichiro Kawamura, Shanawaz M Ghouse

Pageof 2

Frequent Collaborators

5 joint publications

Rafael Moreno

3 joint publications

Martí Farrera-Sal

3 joint publications

Miriam Bazan-Peregrino

2 joint publications

Marcel Costa-García